within Pharmacolibrary.Drugs.ATC.B;

model B02AA01_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 2.5,
    adminDuration  = 600,
    adminMass      = 5.0,
    adminCount     = 1,
    Vd             = 0.00026000000000000003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 1020
  );

  annotation(Documentation(
    info ="<html><body><p>Aminocaproic acid is a synthetic derivative of the amino acid lysine and acts as an antifibrinolytic agent by inhibiting plasminogen activation, thereby reducing fibrinolysis and bleeding. It is primarily used to control excessive bleeding in conditions such as fibrinolytic states (e.g., after surgery, trauma, or bleeding disorders). Aminocaproic acid is approved and in clinical use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy volunteers after oral administration.</p><h4>References</h4><ol><li><p>Kaye, S, et al., &amp; Fletcher, DJ (2016). PHARMACOKINETIC STUDY OF ORAL ε-AMINOCAPROIC ACID IN THE NORTHERN ELEPHANT SEAL (MIROUNGA ANGUSTIROSTRIS). <i>Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians</i> 47(2) 438–446. DOI:<a href=&quot;https://doi.org/10.1638/2015-0138.1&quot;>10.1638/2015-0138.1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27468014/&quot;>https://pubmed.ncbi.nlm.nih.gov/27468014</a></p></li><li><p>Wellington, K, &amp; Wagstaff, AJ (2003). Tranexamic acid: a review of its use in the management of menorrhagia. <i>Drugs</i> 63(13) 1417–1433. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363130-00008&quot;>10.2165/00003495-200363130-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12825966/&quot;>https://pubmed.ncbi.nlm.nih.gov/12825966</a></p></li><li><p>Rey, E, et al., &amp; Olive, G (1992). Vigabatrin. Clinical pharmacokinetics. <i>Clinical pharmacokinetics</i> 23(4) 267–278. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199223040-00003&quot;>10.2165/00003088-199223040-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1395360/&quot;>https://pubmed.ncbi.nlm.nih.gov/1395360</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B02AA01_1;
